Its cardioprotective effect is independent of the presence of T2DM (163)
The most commonly reported side effects in Phase 2 trials were gastrointestinal, including nausea, vomiting, diarrhoea, and constipation, which were generally mild to moderate and tended to improve over time
A drug that produces greater average weight loss may not deliver better outcomes if it is less well tolerated by a specific patient
What are the most common side effects when starting retatrutide
Key readouts include: TRIUMPH-1 (obesity): Participants on the 12 mg weekly dose achieved an average body-weight reduction of roughly 28.3% at 80 weeks and up to 30.3% at 104 weeks , figures that approach outcomes previously associated only with bariatric surgery
In the expert opinion section, the author suggests that once-daily oral semaglutide might not replace the once-weekly subcutaneous semaglutide in treating type 2 diabetes